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Abstract
Interferon inducible transmembrane proteins (IFITMs) are
broad-spectrum antiviral factors. In cell culture the entry of many
enveloped viruses, including orthomyxo-, ﬂavi-, and ﬁloviruses, is inhib-
ited by IFITMs, though the mechanism(s) involved remain unclear and
may vary between viruses. We demonstrate that Sindbis and Semliki
Forest virus (SFV), which both use endocytosis and acid-induced mem-
brane fusion in early endosomes to infect cells, are restricted by the
early endosomal IFITM3. The late endosomal IFITM2 is less restrictive
and the plasma membrane IFITM1 does not inhibit normal infection by
either virus. IFITM3 inhibits release of the SFV capsid into the cytosol,
without inhibiting binding, internalization, trafﬁcking to endosomes or
low pH-induced conformational changes in the envelope glycoprotein.
Infection by SFV fusion at the cell surface was inhibited by IFITM1,
but was equally inhibited by IFITM3. Furthermore, an IFITM3 mutant
(Y20A) that is localized to the plasma membrane inhibited infection by
cell surface fusion more potently than IFITM1. Together, these results
indicate that IFITMs, in particular IFITM3, can restrict alphavirus infec-
tion by inhibiting viral fusion with cellular membranes. That IFITM3 can
restrict SFV infection by fusion at the cell surface equivalently to IFITM1
suggests that IFITM3 has greater antiviral potency against SFV.
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Human interferon inducible transmembrane pro-
teins (IFITMs) are a family of five, 15–17 kDa
membrane-associated proteins, of which three (IFITM1,
2 and 3) appear to function as broad-spectrum inhibitors
of viral replication. Although detailed studies are lacking
for most viruses, work on influenza A virus (IAV) has
suggested that IFITM3, in particular, inhibits viral entry
by interfering with endosomal, low pH-induced fusion
(1–4). However, the precise molecular mechanism(s)
for this inhibition remains unclear, and for some viruses
alternative modes of action have been proposed (5–7).
Alphaviruses, especially Semliki Forest virus (SFV) and
Sindbis virus (SINV), have been used extensively to study
viral entry into cells (8–11). These small (∼75 nm diam-
eter), positive sense, single-stranded RNA viruses were
amongst the first to be shown to use clathrin-mediated
endocytosis and endosomal low pH-dependent fusion to
enter cells (8,10). Despite the wealth of knowledge about
their entry, IFITM-mediated inhibition of alphavirus
infection has not been analyzed in any great detail,
although an overexpression screen has suggested IFITMs
inhibit Chikungunya virus infection but had less affect on
Venezuelan equine encephalitis virus (12). It has also been
suggested that low pH-induced fusion of SFV envelope
glycoprotein expressing cells (fusion from within) can
be inhibited by IFITM1 and IFITM3 (3). Nevertheless,
there is a view that alphavirus infection is not restricted
by IFITMs (13,14). Given the similarities, in terms of
structure and mode of entry, between alphaviruses and
flaviviruses, which are restricted by IFITMs (15–18), we
investigated whether SFV and SINV can also be restricted.
We show that normal infection by both SFV and SINV is
restricted by IFITM3 and, to a lesser extent, by IFITM2,
but not by IFITM1. The expression of IFITM3 does not
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Figure 1: Alphavirus infection is inhibited by IFITM proteins. A549 cells stably expressing HA-tagged IFITM1, 2 or 3 were
infected with SFV (A) or SINV (B) at the indicated MOI (pfu/cell) for 5.5–6 h prior to ﬁxation. Cells were then stained for the respective
viral envelope proteins and the proportion of infected cells counted using an Opera microscope system. Although SINV infection of
A549 cells was not as efﬁcient as SFV, IFITM3-HA expression inhibited infection by both viruses. IFITM2-HA expression had some effect
on SFV infection at lower MOI, but minimal effect on SINV infection. IFITM1-HA had no effect on either virus. These data are from a
representative experiment (n= 2–3) performed with triplicate wells in a 96 well plate. Each bar shows the mean infection percentage
for the three wells and the standard deviation.
affect SFV binding, internalization or entry into early
endosomes, which also contain IFITM3. Moreover, the
SFV E1 glycoprotein undergoes a characteristic low
pH-induced conformational change with similar kinetics
in both IFITM3-expressing and non-expressing cells.
However, release of the viral capsid protein into the cytosol
is inhibited in IFITM3-expressing cells.
SFV infection induced by low-pH fusion with the cell
surface was inhibited by the plasma membrane local-
ized IFITM1, but was equally restricted by IFITM3, even
though this protein is predominantly localized to intra-
cellular compartment and is present at only low levels on
the cell surface. Furthermore, a mutant of IFITM3, which
is localized to the plasma membrane (Y20A), inhibited
infection by plasma membrane fusion more potently than
IFITM1, but did not inhibit the endosomal route of infec-
tion.
Together our results show that (i) alphaviruses
are restricted by IFITMs, (ii) for SFV at least,
IFITM3-mediated restriction appears to affect viral
fusion and cytosolic delivery of the viral capsid, and (iii)
that IFITM1 and IFITM3 have different potencies for
inhibition of SFV infection.
Results
IFITMs can restrict alphavirus infection
To investigate whether IFITMs can restrict infection by
alphaviruses, we used A549 cells stably expressing human
C-terminally HA-tagged IFITM1, 2 or 3 (19,20). Cells were
infected with SFV or SINV at MOIs ranging from 0.1 to
1000 pfu/cell for 5.5–6 h, prior to immunolabelling for
newly synthesized viral envelope glycoproteins (E1/E2) as
a marker of infection. IFITM3-HA inhibited infection by
both viruses (Figure 1). At 1 pfu/cell, IFITM3-HA expres-
sion inhibited SFV infection by ∼95%. Though requiring
a higher MOI to see equivalent levels of infection, replica-
tion of SINV was also inhibited by IFITM3-HA. For both
viruses, IFITM3-HA restriction was less efficient at higher
MOIs (∼20% inhibition at 100 pfu/cell and<10% at 1000
pfu/cell for SFV, and ∼10% inhibition at 100 pfu/cell for
SINV). IFITM2-HA also inhibited SFV infection (∼50% at
1 pfu/cell) but had little activity against SINV. IFITM1-HA
had no activity against either virus.
These data indicate that IFITM3-HA, and to a lesser extent
IFITM2-HA, can restrict infection of A549 cells by two
different alphaviruses, and that the restriction can be sat-
urated with higher levels of input virus.
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IFITM3 endosomal localization and expression levels
impact antiviral activity
The A549 IFITM-HA cells used in Figure 1 were pro-
duced through single cell cloning of lentivirally trans-
duced cells. To further test IFITM3-mediated inhibition,
we used two additional sets of A549 stable cells pro-
duced using puromycin selection. One set (P1) was pro-
duced to stably express C-terminally HA-tagged IFITM1,
2 or 3, or an empty vector control. The other set (P2)
included cells expressing IFITM3-HA, IFITM3-HA with a
Y20A mutation and a GFP control. The Y20A mutation
disrupts a Yxxϕ type endocytosis signal in the IFITM3
N-terminal domain (NTD), causing accumulation of the
protein at the plasma membrane ((21), Figures S1 and 8B).
IFITM3-Y20A-HA allowed us to investigate the impor-
tance of endosomal localization for antiviral activity (see
Figures S1 and 3 for wild type IFITM3-HA localization).
These three sets of cells are denoted as: OS – the original
set produced by single cell cloning (Figure 1), and P1 and
P2 for the puromycin selected cells.
IFITM expression levels in all cells were analyzed by
western blot (Figure 2A). Antibodies against the NTDs
of IFITM1 or IFITM3 were used, as previously described
(20). The OS cells had the highest IFITM expression. P1
and P2 cells had expression levels similar to each other. OS-
and P1-IFITM2-HA had low expression, or poor detection
(detected by cross-reaction from the anti-IFITM3-NTD
antibodies), possibly as a consequence of localization
in more hydrolytic, late endosomal compartments (see
Figure 3).
P1- and P2-IFITM3-HA expressing cells inhibited
SFV in the range of 0.1 to 10 pfu/cell (Figure 2B),
but restriction was reduced compared to that seen in
OS-IFITM3-HA cells (compare Figures 2B with 1A).
At 1 pfu/cell, OS-IFITM3-HA showed ∼95% inhibition
while P1- and P2-IFITM3-HA cells showed ∼70% inhi-
bition. The reduced levels of restriction correlate with
the lower IFITM3-HA expression. P1-IFITM2-HA cells
showed some inhibition of SFV infection, though this was
lower than OS-IFITM2-HA and all IFITM3-HA cells. As
with OS-IFITM1-HA, P1-IFITM1-HA did not restrict
SFV infection. IFITM3-Y20A-HA, which localizes to the
plasmamembrane similarly to IFITM1-HA (Figure S1 and
(20)), also did not inhibit SFV infection, suggesting that
the endosomal localization of IFITM3 is essential for its
anti-SFV activity.
Previously, we noted that OS-IFITM3-HA restriction was
less efficient at high viral input (Figure 1). This effect was
also observed for the P1- and P2-IFITM3-HA cells. Thus,
IFITM3-mediated restriction can be saturated either by
increasing the amount of virus or lowering the level of
IFITM3-HA expression.
Unless otherwise indicated, all subsequent work was per-
formed with OS-IFITM-HA cells.
IFITM3 preferentially localizes to early endosomes
and IFITM2 to late endosomes
The majority of viruses restricted by IFITM3 are believed
to fuse with late endosomes where some studies have
suggested IFITM3 is localized (22,23). SFV by contrast,
has been shown to fuse in early endosomes at pH≤ 6.2
(8,11). Since IFITM3-HA more potently restricted SFV
and SINV than IFITM2-HA, and the endosomal localiza-
tion of the protein is necessary for its antiviral activity, we
investigated IFITM2-HA and IFITM3-HA localization.
Cells were co-immuno-labeled for the IFITM proteins
and markers of early and recycling endosomes [Early
Endosomal Antigen 1 (EEA1) and transferrin receptor
(TfR), respectively] or late endosomes and lysosomes
[CD63 and lysosomal associated protein 1 (LAMP1)].
IFITM3-HA showed more colocalization with TfR and
EEA1 than IFITM2-HA, while IFITM2-HA showed
more overlap with CD63 and LAMP1 than IFITM3-HA
(Figure 3). Image analysis showed that a significant
amount of both IFITM2-HA and IFITM3-HA did not
colocalize with each of the single endosome/lysosome
markers (Figure 3C, D). Given that early endosomes
are heterogeneous and neither EEA1 nor TfR mark the
entire early endosome population, and IFITM2-HA
and IFITM3-HA have somewhat overlapping distribu-
tions, we conclude that in fixed A549 cells IFITM3-HA
is associated more with early endocytic organelles and
IFITM2-HA more with later endocytic compartments.
The higher levels of early endosomal localization of
IFITM3-HAmay explain why this protein more effectively
inhibited SFV and SINV infection than IFITM2-HA,
and the plasma membrane-associated IFITM1-HA and
IFITM3-Y20A-HA proteins.
Trafﬁc 2016; 17: 997–1013 999
Weston et al.
Figure 2: IFITM3 expression levels affect SFV restriction. Two sets of A549 cells stably expressing IFITM-HAs (P1 and P2: See
Materials and Methods) were analyzed for IFITM expression levels and SFV restriction. A) Western blotting was used to analyze the
IFITM expression of all three sets of cells (OS= the original single cell clones used in Figure 1). A, 1, 2 and 3 denote A549, IFITM1,
IFITM2 and IFITM3, respectively. Antibodies against the IFITM1-NTD (which cross-react with IFITM3) or IFITM3-NTD (which cross-react
with IFITM2) were used to analyze IFITM expression. Tubulin was used as a loading control. Fluorescence intensity (int.) of the IFITM and
tubulin bands was quantiﬁed using LiCOR Odyssey software. IFITM band intensities were normalized to tubulin loading and arbitrarily
set relative to the highest band intensity on each blot (OS-IFITM3-HA in both cases). B) The P1 and P2 sets were infected with SFV
across a range of MOIs and analyzed for infection by immunoﬂuorescence, as in Figure 1. In line with lower IFITM expression, P1-
and P2-IFITM3-HA show reduced levels of SFV restriction compared to OS-IFITM3-HA (Figure 1). These data are from a representative
experiment (n= 2) performed with triplicate wells in a 96 well plate. Each bar shows the mean infection percentage for the three wells
and the standard deviation.
IFITM3 expression does not block SFV binding or
endocytosis
Having determined that IFITM3-HA can inhibit
alphavirus infection, and localizes to early endosomes,
we hypothesized that the inhibition of viral protein pro-
duction (the read out for Figures 1 and 2B) was due
to inhibition of viral entry into cells. In order to infect
a cell and replicate, alphaviruses need to deliver their
RNA-containing capsid into the cytosol. Initially the virus
must bind to the cell surface, prior to internalization
by clathrin-mediated endocytosis (CME). Once in the
endosomal system, the low pH environment triggers con-
formational changes in the envelope glycoproteins (E1/E2)
to drive fusion of the viral and endosomal membranes and
capsid release to the cytosol (24). We tested each of these
aspects of the SFV entry pathway to determine the stage at
which IFITM3 restricts infection.
Initially, we investigated whether IFITM-HA expression
affected virus binding to the cell surface. Equal amounts
of virus were added to IFITM-HA expressing A549 cells
for 1 h at 4 ∘C, and the amount of bound virus determined
by western blotting whole cell lysates for E1/E2. Similar
amounts of bound virus were detected in IFITM negative
A549 cells and cells expressing each of the three IFITM-HA
proteins (Figure 4A).
Next, to investigate whether IFITM3-HA affected SFV
endocytosis, we measured virus uptake using a protease
resistance assay (9). SFV was bound to the surface of
cells as previously, and the cells then warmed to 37 ∘C
for 5, 15 or 30min to promote endocytosis. After each
time point, the cells were placed on ice and treated with
subtilisin (25). Samples were lysed and analyzed for
E1/E2 by western blot. To quantify uptake, the band
intensities of E1 (bottom) and E2 (top) were measured
across multiple experiments. Although subtilisin failed
to remove ∼22% of the surface virus, there was a clear
increase in subtilisin resistant virus on warming the
A549 cells to 37 ∘C (Figure 4B). This peaked at 15min
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Figure 3: IFITM2 and IFITM3 are found in endosomal compartments. OS-IFITM2-HA and IFITM3-HA cells were ﬁxed,
permeabilized and stained using an anti-IFITM3-NTD antibody, and markers of early and late endosomes and lysosomes. A)
Example images of cells co-stained for IFITM and transferrin receptor (TfR) and visualized with AF488 (IFITM – green) and AF647
(TfR – magenta) by confocal microscopy. Confocal sections are displayed. B) Example images of cells co-stained for IFITM (AF488) and
LAMP1 (AF647) and imaged as in (A). Nuclei were detected with Hoechst staining. Scale bars represent 15 μm. C and D) Colocalizations
of IFITMs with early endosome markers, TfR and EEA1, or late endosome/lysosome markers, CD63 and LAMP1, were quantiﬁed. Data
are from three independent experiments using between 18 and 21 ﬁelds of view collected using a 63× objective lens. Quantiﬁcation of
overlapping pixels and signiﬁcance testing is described in Materials and Methods. IFITM3-HA shows more overlap with TfR and EEA1
than IFITM2-HA. Conversely, IFITM2-HA shows greater overlap with CD63 and LAMP1 than IFITM3-HA. There are pixels that contain
just IFITM protein or just cellular marker, suggesting the IFITMs are not limited to single compartments. Bars show the mean pixel area
and error bars are the standard deviation. ****p< 0.0001.
when> 75% of the virus was internalized (Figure 4C).
Very similar uptake was seen on IFITM3-HA cells. We
conclude that IFITM3-HA expression does not affect
either binding, or internalization of SFV into A549
cells.
Internalized SFV colocalizes with IFITM3
Since we observed that IFITM3-HA is associated with
early endosomes (Figure 3), we investigated whether inter-
nalized SFV entered IFITM3-HA positive endosomes.
As above, virus was bound and internalized into cells,
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Figure 4: SFV binding to and internalization into IFITM expressing cells A) SFV (200 pfu/cell) was added to A549 cells or
OS-IFITM expressing cells (A, M1, M2, M3) at 4∘C. After 1 h, the cells were washed and analyzed by western blotting for the viral
envelope proteins. Tubulin was used as a loading control. The results indicate similar levels of binding to all four cell lines. B) SFV
(200 pfu/cell) was allowed to bind to cells at 4∘C for 1 h. Endocytic uptake of virus was promoted by warming to 37∘C for 0, 5, 15 or
30min. Cells were then treated with subtilisin at 4∘C to remove surface-bound virus, leaving only internalized virus associated with the
cells. In each blot, controls of samples not treated with subtilisin were loaded to indicate the total cell-associated virus. C) Quantiﬁcation
of E1 and E2 subtilisin resistant band intensity. 3–4 independent experiments were performed. Band intensities of E1 (bottom) and
E2 (top) were determined and adjusted based on tubulin band intensity for each sample. A measure of total cell-associated virus was
determined by averaging band intensity for all untreated time points. The intensity of E1 or E2 at each treated time point was then
set as a proportion of this total. Band intensities were averaged across experiments and plotted to display the percentage of subtilisin
resistant E1 or E2 at each time point.
which were then fixed and immuno-labeled for E1/E2
and IFITM3-HA and analyzed by confocal microscopy
(Figure 5). As a control, these experiments were repeated
in A549 cells that were stained for EEA1 instead of
IFITM3-HA (Figure S2). When kept at 4 ∘C (t= 0) or
warmed for 5min, virus particles were seen as faint
puncta primarily around the cell edges, and there was
little overlap with IFITM3-HA or EEA1. After 10min at
37 ∘C, and at later time points, SFV staining appeared
as larger, increasingly bright, punctae. The increase in
EEA1 puncta intensity seen in Figure S2 was also seen in
mock-infected cells (data not shown), suggesting this may
be due to cooling and warming cells. A time-dependent
increase in the overlap between E1/E2 and IFITM3-HA
(Figure 5B) or EEA1 (Figure S3B) was detected over
multiple experiments.These data suggest that endocytosed
SFV was delivered to IFITM3-HA positive endosomes.
These observations were further confirmed by electron
microscopy (EM), which revealed that SFV particles were
internalized by CME (Figure S3). Subsequently, SFV par-
ticles were detected in multivesicular bodies that could
be co-labeled for SFV and IFITM3-HA (Figure S4), fur-
ther demonstrating that virus particles were delivered into
IFITM3-HA containing endosomes.
To confirm that we were investigating time points relevant
to infection, the kinetics of SFV capsid release in A549
cells were determined. SFV penetration of endosomes is
low pH-dependent. Thus, ionophores such as monensin,
that rapidly dissipate cellular low pH gradients, can be
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Figure 5: Internalized SFV colocalizes
with IFITM3. A) SFV (50 pfu/cell) was bound
to cells at 4∘C for 1 h. After washing, the
cells were warmed to 37∘C for the indicated
times, then ﬁxed and labeled for SFV E1/E2
and OS-IFITM3-HA (via the HA-tag) and visu-
alized with AF488 (green, E1/E2) and AF647
(magenta, HA). Confocal sections are dis-
played. E1/E2 labelling can be seen as small
puncta mainly around the cell periphery at 0
and 5min, with little overlap of SFV E1/E2 and
IFITM3-HA. At later time points (10min and
onwards) larger and brighter puncta become
visible closer to the nucleus, and overlap of
SFV E1/E2 and IFITM3-HA is seen, which
increases with time. Many IFITM3-HA posi-
tive, SFV negative puncta, can be seen sug-
gesting that not all IFITM3-HA containing
endosomes receive virus. By contrast, many
SFV positive puncta co-label for IFITM3-HA
at 20 and 30min. Nuclei were detected with
Hoechst staining. Scale bar represents 15 μm.
B) The overlap between green (SFV E1/E2)
and magenta (HA) pixels was quantiﬁed (see
Materials andMethods). A total of three inde-
pendent experiments were performed, and six
images taken at 63× magniﬁcation for each.
The average ratio of the relative area of over-
lapping pixels (green and magenta) to green
pixels from each experiment is plotted, with
the standard deviation used for the error bars.
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Figure 6: SFV is exposed to acidic pH in IFITM3 expressing cells. SFV (200 pfu/cell) was bound to A549 (lanes 1–12) or
OS-IFITM3-HA expressing cells (lanes 13–18) at 4∘C for 1 h. The cells were then washed and either kept at 4∘C (lanes 1–4) or warmed
to 37∘C to allow virus uptake (lanes 5–18), as indicated. In lanes 3–4, cells with bound virus were brieﬂy (3 min) treated with pH 5.5
medium at 37∘C, or in lanes 5–6, were warmed to 37∘C for 30min in medium containing baﬁlomycin A1 (Baf A). Subsequently, all
cells were placed on ice, lysed with 1% Triton X-100 and half of the lysate treated with trypsin at 37∘C as indicated. All samples were
then analyzed by non-reducing SDS-PAGE and western blotting for SFV E1/E2 and tubulin as a loading control. Following a pH 5.5 pulse
(lanes 3–4), or incubation at 37∘C (lanes 7–18), a high MW band corresponding to the acid-induced, trypsin-resistant, E1 homotrimer
(HT) was seen. This band was absent at 0 min (lanes 1–2) and in Baf A-treated samples (lanes 5–6), indicating it is the low pH-induced
form of E1.
used in time of addition experiments to determine when
incoming virus has passed through the pH sensitive stage
of entry (26). Virus particles were bound toA549 cells prior
to warming to promote uptake, as previously. Monensin
was added at times between 0 and 30min. When added
at 0min, monensin nearly completely abolished infec-
tion (Figure S5). However, when added at later times, an
increasing percentage of cells became infected. By 30min,
monensin addition had almost no inhibitory effect (Figure
S5), suggesting the majority of infectious virus had pen-
etrated the cells. Therefore, analysing SFV internalization
within the first 30min of warming is relevant to infection.
SFV is exposed to acidic pH in IFITM3 expressing cells
We next investigated whether the viral glycoproteins
received the appropriate low pH trigger to become fuso-
genic in IFITM3-HA expressing cells. The acid-induced
conformational changes in the E1/E2 complex generate a
homotrimeric (HT) form of E1 that is resistant to trypsin
digestion (27). Again, SFV was bound to cells and allowed
to internalize for 0, 5, 15 or 30min at 37 ∘C. As a positive
control, virus particles bound to cells at 4 ∘C were treated
with pH 5.5 medium for 3min at 37 ∘C to activate the
fusion protein directly at the cell surface. As a negative
control, cells were pre-treated with bafilomycin A1 (Baf
A; a vacuolar ATPase inhibitor) for 15min at 37 ∘C, prior
to binding and internalization of virus particles in the
presence of Baf A. After appropriate treatments, cells were
lysed and the lysates treated with trypsin, or not, and the
viral E1/E2 proteins analyzed by western blot. Samples
were not heated prior to SDS-PAGE as this can dissociate
the E1 HT. With 0min of internalization, the monomeric
forms of E1 and E2 were seen with the expected molecular
weights (MW) of ∼50 kDa (Figure 6, lane 1). After trypsin
treatment of samples kept at 4∘C, the E1/E2 bands were
undetectable (lane 2). Transient low pH treatment of
surface-bound virus induced the formation of a high MW
band that was resistant to digestion with trypsin (lanes 3
and 4), corresponding to the E1 HT.This trypsin-resistant,
high MW band was seen, with increasing intensity, when
virus was allowed to internalize into A549 cells for 5, 15
or 30min (lanes 7–12), but not when virus was internal-
ized into Baf A treated cells (lanes 5 and 6). When SFV
was internalized into IFITM3-HA expressing cells the
trypsin-resistant, high MW band appeared with kinetics
similar to those seen in IFITM-negative A549 cells (lanes
13–18). We therefore conclude that IFITM3-HA does not
interfere with acidification of endosomes, virus trafficking
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to these compartments, or the conformational changes
necessary for the viral glycoprotein to become fusogenic.
IFITM3 expression inhibits release of SFV capsid to the
cytosol
The final step in the SFV entry pathway is release of the
capsid into the cytosol. To determine whether IFITM3
affects this step, SFV particles were bound and internalized
into cells, which were then analyzed by immunofluores-
cence staining for the SFV capsid protein. Between 0 and
20min, in both A549 and IFITM3-HA cells, punctae of
virus were seen at the cell surface and subsequently within
endosomes (Figure 7A), as observed by E1/E2 labelling
(Figures 5 and S3). In general the labelling was weak, even
after treatment with Triton, presumably because the capsid
protein is poorly accessible when packed within virions.
At 40min in A549 cells, diffuse cytosolic fluorescence
was seen, which was further increased at 60min. This
cytosolic fluorescence was not seen following SFV uptake
into monensin-treated A549 cells, or in IFITM3-HA cells,
suggesting the diffuse fluorescence is from viral capsid
protein released into the cytosol. To develop a more
quantitative analysis of this capsid release, images were
analyzed over multiple experiments to determine the
mean cytosolic fluorescence intensity in each cell. This
quantification indicated that over time there is an increase
in the cytosolic capsid protein-associated fluorescence
in A549 cells, that is not seen in monensin-treated A549
or IFITM3-HA cells (Figure 7B). In addition, in these
latter cells the punctae of SFV staining appeared brighter
at later times, suggesting that non-fused virus particles
accumulated within endosomes (Figure 7A). Together
these observations indicate that IFITM3-HA expression
inhibits release of SFV capsid into the cytosol.
IFITM1 and IFITM3 can inhibit SFV infection by fusion
at the plasma membrane
Our data indicate that IFITM3 is primarily localized
to early endosomes and can block SFV capsid release
into the cytosol. We therefore investigated whether
IFITM3-mediated restriction could be bypassed by fusion
of SFV at the cell surface, and whether plasma membrane
localized IFITM1 (20) or IFITM3-Y20A (Figure S1) could
restrict entry at this site. Cells were pre-treated with Baf A
for 15min at 37∘C to inhibit SFV entry via the endocytic
route, prior to binding virus to the surface at 4∘C for 1 h.
The cells were then treated with pH 5.5 medium for 3min
at 37∘C to induce fusion at the plasma membrane, prior to
returning to pH 6.8 medium containing Baf A for 5.5–6 h
at 37∘C to allow production of E1/E2 proteins as a read out
for infection. As controls, cells with bound virus were given
a 3min pH6.8 pulse and treated with DMSO or Baf A.
Through the normal endocytic route (pH 6.8 DMSO),
between ∼65% and ∼80% of A549 cells (OS, P1 and P2),
were infected with SFV (5 pfu/cell), and infection was
inhibited by>90% with Baf A treatment (pH 6.8 Baf A;
Figure 8A). When cells were pre-incubated with Baf A
and transiently treated with low pH medium, ∼20–50%
of cells were infected (pH 5.5 Baf A; Figure 8A). The
Baf A pre-treatment step did not affect the result, since
pre-treatment with DMSOmedia, followed by Baf Amedia
for the infection period (pH 5.5 DMSO/Baf A) showed
similar results. This bypass of Baf A inhibition with pH 5.5
treatment is the level of infection by direct fusion at the
plasma membrane. It appeared that the three A549 cells
had different permissiveness to infection by plasma mem-
brane fusion.TheparentalOS-A549 cells were the least per-
missive to plasmamembrane fusion; the P1-A549 cells (sta-
bly transfectedwith an empty puromycin resistance vector)
were the most permissive, while the P2-A549 cells (stably
transfected with a GFP construct) were in the middle. We
speculate that the differentmanipulations of these cellsmay
be responsible for the variability.
Virus entering through the endocytic route infected OS-
and P1-IFITM1-HA cells, similarly to A549 controls, and
Baf A inhibited this. When virus bound to the surface of
both OS- and P1-IFITM1-HA cells was transiently treated
with pH 5.5 medium, the infection percentage was con-
sistently lower than that seen in similarly treated A549
cells (Figure 8A). In the OS set, the fact that A549 con-
trol cells were not easily infected by plasma membrane
fusion meant that inhibition by IFITM1-HA was modest.
However, in the P1 set, the difference between infection by
plasma membrane fusion of A549 and IFITM1-HA cells
was much greater, arguing that IFITM1-HA can inhibit
plasma membrane fusion to some extent.
Plasma membrane localized P2-IFITM3-Y20A-HA did
not restrict SFV infection through the endocytic route
(Figures 8A and 2B). However, when surface-bound virus
was low pH treated, P2-IFITM3-Y20A-HA inhibited
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Figure 7: IFITM3 expression inhibits SFV
capsid release. A) SFV (200 pfu/cell) was bound
to cells for 1 h at 4∘C prior to incubation at
37∘C for the indicated times. At each time point
the cells were ﬁxed and permeabilized with 0.1%
Triton-X100 and labeled with serum against the
SFV capsid, which was detected with AF594. Con-
focal sections are displayed. Following internaliza-
tion, virus particles were detected in cells, indi-
cated by the typical punctate association of virus
with endosomes. By 40min after warm-up diffuse
cytosolic ﬂuorescence was seen in A549 cells, indi-
cating release of the viral capsid protein to the
cytosol. In A549 cells treated with 10 μMmonensin,
and in OS-IFITM3-HA expressing cells, the staining
remains associated with puncta and the cytoso-
lic staining was not observed even at 60min after
warm-up. Nuclei were detected with Hoechst stain-
ing. Scale bar represents 15 μm. B) Quantiﬁcation
of cytosolic ﬂuorescence and signiﬁcance testing is
described in Materials and Methods. The data are
from three independent infections with 3–7 images
taken at each condition, with a total of at least
60 cells analyzed per cell line, per condition. Data
presented is the average ﬂuorescence intensity, nor-
malized to the background intensity at 0 min of
warming. *p< 0.05, **p< 0.01.
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Figure 8: IFITM1 and IFITM3 can inhibit SFV infection by fusion at the cell surface. A) OS-, P1- and P2-IFITM-HA cells
were infected by SFV through plasma membrane fusion. Cells were pre-treated with either DMSO or baﬁlomycin A1 (Baf A) prior to
addition of SFV (5 pfu/cell) for surface binding at 4∘C for 1 h (in the presence of DMSO or Baf A). Surface-bound virions were then
allowed to enter cells by endocytosis (pH 6.8) or fused directly at the cell surface (pH 5.5). pH 6.8 media containing DMSO or Baf A
(matched to the pre-treatment) was then added to the cells, which were incubated for 5.5–6 h at 37∘C to allow infection. As a control
for the Baf A pre-treatment, cells were instead pre-treated with DMSO, then incubated with Baf A containing media for the infection
period (pH 5.5 D/B). Cells were ﬁxed and infection determined by immunoﬂuorescence microscopy. Baf A inhibited infection through
the endocytic route (black bars compared to white bars). Low pH treatment resulted in bypass of Baf A inhibition, indicative of cell
surface fusion (green and magenta bars). The bars indicate the mean infection percentages from three independent experiments (each
containing triplicates for each sample) with standard deviation shown as the error bars. Statistical signiﬁcance was determined using
normalized infection values, comparing pH 5.5 DMSO/Baf A (green) or pH 5.5 Baf A (magenta) of A549 samples with IFITM samples, as
detailed in the Materials and Methods section. *p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001. B) OS-, P1- and P2-IFITM-HA
cells were labeled with anti-HA antibodies either intact (I) or following permeabilization (P), detected with AF647, and analyzed by
ﬂow cytometry to determine the relative levels of cell surface IFITM protein. As controls, cells were either incubated with no antibody
or secondary antibody only. The mean ﬂuorescence intensity (MFI), relative to the no antibody control for each cell line is displayed.
Plots are representative of 3–4 independent experiments.
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infection by ∼95% (Figure 8A). This inhibition is
greater than that seen for either OS- or P1-IFITM1-HA
(Figure 8A), even though P2-IFITM3-Y20A-HA expres-
sion levels were lower than those of IFITM1-HA
(Figure 2A).
Endocytic infection was low in all IFITM3-HA cells, with
OS-IFITM3-HA being the most restrictive (Figure 8A as
in Figures 1 and 2B). Baf A reduced this low level infection
to< 1%. Surprisingly, there was no increase in infection of
these cells following pH5.5 treatment of cell surface-bound
virus, and the infection was consistently lower than that
seen in all A549 cells (Figure 8A). Indeed, OS-IFITM3-HA
had the lowest infection percentages, even lower than
either OS- or P1-IFITM1-HA. IFITM3-HA also inhibited
SFV infection via plasma membrane fusion in the P1- and
P2- cells to a similar extent to that seen with IFITM1-HA.
It was interesting to see such potent inhibition of cell
surface fusion by IFITM3-HA since immunofluorescence
microscopy indicated that the majority of IFITM3-HA
is located in endosomal compartments (Figure 3) rather
than at the cell surface. To confirm these observations,
cells were stained either intact, or following permeabi-
lization, and analyzed by flow cytometry to determine
levels of each IFITM protein at the cell surface. Anti-
bodies against the C-terminal HA-tag were used as we,
and others, have shown the IFITM proteins to have
a type-II transmembrane topology with the C-terminal
domain facing the extracellular space (20,28,29).Themean
fluorescence intensity (MFI) of labeled OS-IFITM1-HA,
P1-IFITM1-HA and P2-IFITM3-Y20A-HAwas essentially
equivalent between intact and permeabilized cells, suggest-
ing the HA-tag is accessible at the cell surface (Figure 8B).
Conversely, for all three IFITM3-HA cases, significant
labelling was only detected when cells were permeabilized,
suggesting the majority of IFITM3-HA is in intracellular
pools (Figure 8B). TheMFI of intact IFITM3-HA cells was
slightly above background levels, suggesting some surface
IFITM3-HA (as we have previously observed (20)),
Overall, despite low levels of cell surface expression
(Figure 8B), IFITM3-HA inhibited SFV infection by fusion
at the plasma membrane to a similar or greater extent than
IFITM1-HA (Figure 8A). Presumably IFITM3-HA that
transiently transits the cell surface en route to endosomes
is responsible for this inhibition (20,21,30). From this, we
conclude that IFITM3-HA is a more potent inhibitor of
SFV fusion than IFITM1-HA.
Discussion
IFITM proteins restrict the replication of a wide range
of enveloped viruses, and at least one non-enveloped
virus (22,23). However, to date there is little evidence
that IFITMs restrict alphavirus infection. Here we show
that IFITM3, and to a lesser extent IFITM2, can inhibit
the replication of two alphaviruses in A549 cells. Using
SFV, we show that virus binding, endocytosis, delivery to
endosomes and exposure to acidic pH are unaffected by
IFITM3 expression. The viral envelope proteins undergo
an acid-dependent conformational change with similar
kinetics in IFITM3 expressing and non-expressing cells.
However, the viral capsid protein does not appear in the
cytosol of IFITM3 expressing cells. These results indi-
cate that IFITM3 restricts SFV infection by inhibiting
endosomal fusion and/or uncoating of the viral capsid.
To date the broad antiviral activity of IFITMs has been
largely seen through the use of retrovirus-based pseudo-
type reporter systems (22). However, for influenza A virus
(IAV) the inhibitory activity of IFITM3 has been better
characterized and appears to occur following virus endo-
cytosis and delivery to endosomes, but prior to detection of
the viral RNA in the nucleus (1). Nevertheless, the precise
mechanism(s) of IFITM3-mediated restriction remains
unclear. Based on lipid mixing assays, Desai et al. suggest
that IFITM3 inhibits IAV genome release from endosomes
after the formation of hemifusion intermediates (4). While
Li et al. suggest that IFITM proteins inhibit the initial lipid
mixing events leading to hemifusion, based on cell–cell
fusion experiments with IAV and the retrovirus JSRV (3).
Our experiments with SFV indicate that virus delivery to
acidic endosomes and the initial steps in the fusion reac-
tion, including low pH-induced conformational changes in
the viral envelope protein are unaffected by IFITM3. Nev-
ertheless, delivery of the capsid to the cytosol is blocked,
suggesting that IFITM3 inhibits membrane fusion or, pos-
sibly, uncoating after fusion has occurred.
It is interesting to note that IFITM1 did not inhibit endo-
cytic entry of either alphavirus since many other viruses
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show at least some sensitivity to this protein (22). Fur-
thermore, dengue virus, a type II fusion protein express-
ing virus, similar to alphaviruses, is restricted by IFITM1,
2 and 3 (17). We speculate endocytic uptake and fusion
with early endosomes allows SFV to escape inhibition
from the plasma membrane localized IFITM1, in this
system. However, why the endocytic route of alphavirus
entry is not inhibited by IFITM1, while other endocytosed,
low pH-dependent viruses (such as dengue) are inhibited,
remains unclear.
Previously the effect of IFITM protein expression on SFV
E1/E2-mediated fusion from within (cell–cell fusion facil-
itated by E1/E2 expressed on the cell surface and exposure
of cells to low pH medium) was reported (3). In that study
IFITM1 and IFITM3 were found to inhibit syncytium for-
mation. In agreement, we also see that both IFITM1 and
IFITM3 can inhibit infection by SFV, when virus is fused at
the cell surface. Immunofluorescence (Figure 3 and (20)),
EM (data not shown) and flow cytometry (Figure 8B) show
lower levels of IFITM3 at the cell surface than IFITM1.
It is therefore interesting that IFITM3 seems to be able
to inhibit infection by cell surface fusion to an equiva-
lent or greater extent than IFITM1 (Figure 8A). Further-
more, when IFITM3 is relocated to the plasma mem-
brane (IFITM3-Y20A) greater inhibition of infection was
seen compared to IFITM1 (Figure 8A). We conclude that
IFITM3 has greater potency for inhibiting SFV fusion
than IFITM1. Understanding this difference may provide
insights to the mechanism(s) underlying the ability of
IFITMs to restrict viral replication.
Finally, we observed that the antiviral action of IFITM3
can be saturated by increasing the amount of virus, and is
also influenced by the level of IFITM protein expression
(Figures 1 and 2). Type I interferon treatment of A549 cells
results in similar levels of IFITM expression as seen in the
P1 and P2 cell sets (data not shown).This ability to saturate
IFITM3 restriction could be explained if there is a level of
direct interaction between IFITM3 and SFV fusion sites.
Whether IFITM3 is recruited to sites of membrane fusion,
or is localized to specificmembrane domains conducive for
fusion, remains to be established.
With the wealth of experimental data on SFV mem-
brane fusion, using alphaviruses as a model may aid our
understanding of the molecular mechanism(s) underlying
IFITM-mediated inhibition of viral infection. Elucidating
these mechanisms may help to generate novel therapeutic
strategies that could be applied against a broad range of
both human and animal pathogens, and to further our
understanding of membrane fusion, a phenomenon that
underpinsmanymore biological functions than viral entry.
Materials and Methods
Cell lines and viruses
The previously described (19,20) original set (designated OS) of A549
cells stably expressing C-terminal HA-tagged human IFITM1, 2 or 3, were
cultured in Ham’s F-12 GlutaMAX media (all cell culture reagents were
from Life Technologies, unless otherwise stated), supplemented with 10%
(v/v) foetal calf serum [FCS (PAA)] and 1% (v/v) Penicillin/Streptomycin
(Pen/Strep, 10 000 units/mL, 10 000 μg/mL), as previously described (20).
The puromycin 1 (P1) set of cells, which consists of A549 cells sta-
bly expressing an empty puromycin resistance vector or C-terminal
HA-tagged IFITM1, 2 or 3, and the puromycin 2 (P2) set of cells, which
consists of A549 cells stably expressing GFP or C-terminal HA-tagged
IFITM3 or IFITM3-Y20A, were cultured in the same conditions. BHK-21
cells were cultured in Glasgow-MEM supplemented with 5% FCS, 1%
Pen/Strep and 10% (v/v) tryptose phosphate broth (Sigma).
SFV stocks were prepared as described (8). Briefly, BHK-21 cells were
infected with SFV at an MOI of 0.05 pfu/cell and cultured for 22 h
(h). Supernatants were collected and cleared of cellular debris by low
speed centrifugation and the virus concentrated by ultracentrifugation
(100,000× g for 2.5 h at 4 ∘C). Virus pellets were resuspended in TNbuffer
(100mM NaCl, 50mM Tris pH 7.6) and stored at −80∘C. Virus infectivity
was determined on BHK-21 cells by serial dilution plaque assay.
Sindbis virus (SINV)AR339 (a kind gift fromDr. PennyPowell, University
of East Anglia, Norwich, UK) stocks were prepared as for SFV.
Antibodies
Rabbit sera against the SFV envelope glycoprotein (E1/E2) and the
capsid protein were previously described (31). Rabbit anti-SINV sera
was provided by Dr. Penny Powell (University of East Anglia, Norwich,
UK). Rat anti-HA (clone 3 F10, Roche), mouse anti-HA (clone HA.11
16B12, Covance), rabbit anti-IFITM1-N-terminal-domain (NTD),
rabbit anti-IFITM3-NTD, mouse anti-tubulin, goat anti-rabbit Alex-
aFluor (AF)488, goat anti-rat AF647, goat anti-rabbit IRDye 680 and
goat anti-mouse IRDye 800 were all previously described (20). Mouse
anti-transferrin receptor (TfR, 1mg/mL, clone MEM-189, Abcam),
mouse anti-EEA1 (250 μg/mL, BD Biosciences), mouse anti-CD63 (32),
goat anti-rabbit AF594 and goat anti-mouse AF647 (both 2mg/mL, Life
Technologies). All antibodies were diluted as described below.
Viral infections
To infect A549 cells, virus was diluted to the required MOI in F-12 infec-
tion media [F-12 media supplemented with 0.2% (w/v) bovine serum
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albumin (BSA) and 10mM HEPES (both Sigma), pH 6.8], and incubated
with cells for 5.5–6 h at 37 ∘C. Infected cells were detected by immunoflu-
orescence staining, as described below, using antibodies against the viral
envelope glycoproteins. An Opera confocal microscope (Perkin-Elmer)
was used to image cells and the number of infected cells counted using
the COLUMBUS software (Perkin-Elmer).
Virus binding to the cell surface
SFV particles were bound to the cell surface to promote synchronous
internalization in the indicated experiments. Virus was diluted in 4 ∘C
bindingmedia [BM: RPMImediumwithout bicarbonate (Sigma), supple-
mentedwith 0.2%BSA, 10mMHEPES and 10mMMES (Sigma) at pH 6.8]
and added to cells at the indicated MOIs for 1 h with gentle shaking. The
cells were then rinsed twice with cold BM to remove unbound virus, prior
to any further treatment, as detailed below.
SFV internalization
SFV internalization into cells was analyzed by immunofluorescence and
EM (described below) or biochemically. For light microscopy analysis,
SFV was bound to cells at an MOI of 50 or 200 pfu/cell prior to treatment
with pre-warmed pH6.8 BM and incubation at 37∘C for the indicated
times. Cells were then fixed, permeabilized and stained for E1/E2 or the
capsid protein.
For the biochemical investigation of internalization, SFV (200 pfu/cell)
was bound to cells at 4∘C. The cells were then washed and warmed for
the indicated times, or left on ice. Surface-bound virus was removed by
treatment with subtilisin [2mg/mL in PBS (Sigma)] for 1 h at 4∘C with
gentle shaking. Subtilisin was inactivated by addition of 1mM PMSF in
PBS with 30mg/mL BSA. Cells were collected and washed with PBS
containing 0.2% (w/v) BSA to remove detached virus. Internalized virus
was then measured by western blot analysis of SFV E1/E2 in whole cell
lysates. Subsequently, the band intensities were quantified: A measure
of total cell-associated virus was determined by averaging the E1 or E2
band intensities at each time point, without subtilisin treatment. The E1
or E2 intensity at each subtilisin treated time point was then set as a
proportion of this averaged total, thus giving a percentage of subtilisin
resistant (internal) E1 or E2. All intensity values were adjusted based on
the tubulin loading control. These values were calculated and averaged
over 3–4 experiments.
SFV endosomal penetration
To determine the kinetics of endosomal penetration in A549 cells, 5
pfu/cell SFV was added and allowed to bind. Subsequently, F-12 infection
media, pre-warmed to 37∘C, containing DMSO or 10 μM monensin, was
added to cells (t= 0). At indicated time points between 3 and 30min,
DMSO media was replaced with F-12 infection media containing 10 μM
monensin. Cells were then incubated at 37∘C for 5.5–6 h, after which they
were fixed and analyzed for infection by immunofluorescencemicroscopy
for the E1/E2 proteins.
Immunoﬂuorescence staining and microscopy and ﬂow
cytometry
Immunofluorescence staining and microscopy was performed as previ-
ously described (20) with the exception that 0.1% Triton-X100 (Tx100,
Sigma) was used for permeabilization in experiments to detect the SFV
capsid protein.
For flow cytometry, cells were detached from plates using 5mM EDTA
and fixed in suspension with 3% formaldehyde for 15min at room tem-
perature. Formaldehyde was quenched with 50mM NH4Cl in 0.2% BSA
diluted in PBS (PBS/BSA) for 15min at room temperature. Samples were
then permeabilized with 0.05% saponin in PBS/BSA [permeabilization
buffer (PB)] or incubated with PBS/BSA alone for 30min at room tem-
perature, prior to labelling with rat anti-HA antibody for 1 h at room
temperature (either in PB or PBS/BSA as appropriate). Cells were washed
3× with the appropriate solution and labeled with goat anti-rat AF647 for
45min at room temperature. As controls, samples were incubated with no
antibodies, or incubated with only AF647. Cells were washed 3×with PBS
and subject to flow cytometry (LSR-II; BD Bioscience). Cells were gated
on forward and side scatter and analyzed for fluorescence intensity. Data
were processed using FLOWJO (v10.1r5) software (Tree Star).
Antibodies were used at the following pre-determined dilutions
form stocks (listed above): anti-HA 1:100, anti-IFITM1-NTD 1:200,
anti-IFITM3-NTD 1:200, anti-SFV E1/E2 1:500, anti-SFV capsid 1:500,
anti-SINV E1/E2 1:500, anti-TfR 1:200, anti-EEA1 1:200, anti-CD63
1:10 000 and anti-LAMP1 1:500. All secondary antibodies were used at
1:500.
Image analysis
Image analysis of colocalization between IFITM-HA and cellular markers
was performed using IMAGEJ software as previously described (20). For
the analysis of SFV E1/E2 colocalization with EEA1 or IFITM3-HA this
procedure was slightly altered. Confocal sections were acquired and the
multi-channel images of E1/E2 (green) co-stained with HA or EEA1
(magenta) were split into the component channels. These images were
processed with an ‘AND’ function to generate a new image containing
only pixels that are both green AND magenta (‘overlapping pixels’). A
threshold was set to remove background fluorescence, and the area of the
remaining pixels was quantified. These ‘overlapping pixels’ were removed
from the E1/E2 image, a threshold set, and the area of the remaining ‘green
pixels’ was quantified. Relative pixel areas were then used to calculate the
ratio between ‘overlapping pixels’ and ‘green pixels’ to determine the level
of overlap between E1/E2 and the cellular proteins.
To quantify the SFV capsid cytosolic fluorescence, confocal sections were
collected as displayed in Figure 7A and analyzed using IMAGEJ software
as follows: The channels containing the nuclei and capsid staining were
separated. Nuclei were segmented and any signal in the capsid channel
that fell within the nuclei area was assumed to be non-specific and
removed from the image. A threshold was then applied to these capsid
images to only detect virus puncta, which were similarly removed, and the
remaining signal was deemed to be cytosolic. Individual cells were then
segmented and the mean fluorescence in each cell calculated.
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Significance testing was performed using unpaired student’s T-tests and
GRAPHPAD PRISM software to compare the mean values of overlapping
pixels for colocalization or the difference between mean capsid cytosolic
fluorescence.
Electron microscopy
Epon section EM: 1000 pfu/cell SFV was added to cells grown on cov-
erslips and allowed to bind as above. Cells were subsequently washed
and warmed to allow internalization for the indicated times. The cover-
slips were fixed in EM-grade 2% paraformaldehyde/2% glutaraldehyde
(TAAB Laboratories Equipment, Ltd.) in 0.1 M sodium cacodylate, secon-
darily fixed for 1 h in 1% osmium tetraoxide/1.5% potassium ferricyanide
at 4∘C and then treated with 1% tannic acid in 0.1 M sodium cacody-
late for 45min at room temperature. Samples were then dehydrated in
sequentially increasing concentration of ethanol solutions, and embedded
in Epon resin. Coverslips were inverted onto prepolymerized Epon stubs
and polymerized by baking at 60∘C overnight. The 70 nm thin sections
were cut with a Diatome 45∘ diamond knife using an ultramicrotome
(UC7; Leica). Sections were collected on 1× 2mm formvar-coated slot
grids and stained with Reynolds lead citrate.
Immunolabelling EM: 5000 pfu/cell SFV was added to cells and allowed
to bind and internalize as above. As previously described (20), cells were
fixed with EM-grade 4% (w/v) paraformaldehyde in 0.1M phosphate
buffer pH 7.4, infused with 2.3 M sucrose, supported in 12% (w/v) gelatin
and frozen in liquid nitrogen. Ultrathin (70 nm) cryosections were cut at
−120∘C and picked up in 1:1 2.3 M sucrose: 2% methylcellulose. Sections
were labeled with primary antibody (mouse anti-HA 1:400), followed
by rabbit anti-mouse intermediate antibody (1:180, DAKO) and protein
A-gold. For double labelling experiments, sections were treated with
1% glutaraldehyde in PBS after the first protein A-gold incubation and
quenched in 15mMglycine before repeating the single labelling procedure
with the second primary antibody (anti-E1/E2) and a different sized
proteinA-gold, as described (33). Finally, sectionswere contrast stained in
1:9 solution of 4% uranyl acetate: 2% methylcellulose solution pH4.0. All
samples were imaged using a transmission electron microscope (Tecnai
T12; FEI) equipped with a charge-coupled device camera (SIS Morada;
Olympus).
Antibodies were used at the following pre-determined dilutions from
stocks (listed above): SFV E1/E2 1:50, mouse anti-HA 1:400.
SFV plasma membrane fusion
Cells, in a 96 well plate format, were pre-incubated with either DMSO or
100 nM bafilomycin A1 (Baf A) in BM for 15min at 37∘C. Cells were then
placed on ice and washed with cold BM containing DMSO or Baf A prior
to addition of 5 pfu/cell SFV to bind to the cell surface (in the presence
of Baf A or DMSO). The cells were washed to remove unbound virus and
treated with 37∘C BM (containing DMSO or Baf A) adjusted to pH 5.5 for
3min (or pH 6.8 as control), to trigger viral fusion at the cell surface. Cells
were subsequently incubated for 5.5–6 h in F-12 infectionmedia contain-
ing DMSO or Baf A. Control samples, pH 6.8 DMSO, were treated with
F12 infection media containing DMSO, allowing viral entry through the
normal endosomal route. Cells pre-treated with Baf A and pH6.8 media
were incubated with infection media containing Baf A, allowing endo-
cytosis but inhibiting low pH-induced viral fusion in endosomes. Cells
pre-treatedwith Baf A and given a pH 5.5 pulse were incubatedwith infec-
tion media containing Baf A to trigger fusion at the plasma membrane,
while inhibiting acidification of endosomes, such that the low pH trigger
was only received at the plasma membrane. Cells pre-treated with DMSO
and given a pH 5.5 pulse were incubated with infection media contain-
ing Baf A, to again block endosomal acidification and as a control for Baf
A pre-treatment. Infected cells were detected by immunofluorescence, as
described above, using antibodies against E1/E2. Three random epifluo-
rescence images, at 20×magnification, were taken for each well and ana-
lyzed for infection percentage using IMAGEJ software. Briefly, nuclei were
segmented to detect the total number of cells per field. The segmented
nuclei were super-imposed on the fluorescence channel marking infected
cells (E1/E2 stained cells) and a ring of 10 pixels was expanded around
each super-imposed nuclei. The E1/E2 fluorescence intensity within this
ring was used to score cells as infected or uninfected. The percentage of
infected cells was determined for each image and used to determine the
percentage of infected cells per well. All infectionswere carried out in trip-
licate wells, and the mean infection percentage calculated. In order to test
statistical significance of inhibition all infection percentages were set rel-
ative to the A549 pH6.8 DMSO condition within each cell line set (such
that OS-IFITMs were only compared to OS-A549, for example), thus giv-
ing a measure of the relative infection percentage induced by the pH 5.5
treatments. The difference in relative infection percentages was then ana-
lyzed across experiments using unpaired student’s T-tests in GRAPHPAD
PRISM software to compare the difference in relative infection percentage
from pH5.5 treatments in A549 controls against IFITM expressing cells.
SFV E1 trypsin insensitivity
Cells were initially pre-incubated with either DMSO or 100 nM Baf A in
BM as described for SFV plasma membrane fusion. Virus was added at
an MOI of 200 pfu/cell. Where indicated, cells with bound virus were
warmed to 37∘C to allow virus uptake (with Baf A as labeled), briefly
(3min) treated with pH 5.5 BM, or left on ice. Cells were lysed in 60 μL 1%
Tx100 in PBS for 15min on ice, and the nuclei removed by centrifugation.
40 μL of cell lysate were divided in two. One sample was mixed with 20 μL
trypsin [800 μg/mL in 1% Tx100 (Sigma)] and incubated for 10min at
37 ∘C, the other with 20 μL 1% Tx100. Both samples were then mixed
with 20 μL of soybean trypsin inhibitor [2mg/mL (Sigma)]. Finally, 6×
non-reducing Laemmli sample buffer (LSB) was added and an equal
volume of each sample was separated by SDS-PAGE and western blotted
for SFV E1/E2, as described below. Samples were not heated prior to
SDS-PAGE to maintain the E1 homotrimer.
Western blotting
Unless otherwise indicated, cell lysates were produced by incubating
cells with Tx100 lysis buffer [1% (v/v) Tx100, 150mM NaCl, 50mM
Tris–HCl at pH 8.0] containing 1× complete protease inhibitor cocktail
(Roche) for 15min on ice. Nuclei were removed by centrifugation and the
protein concentrations determined using the bicinochoninic acidmethod
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(Thermo Scientific). Equal amounts of protein for each sample were
mixed with 3× LSB containing 100mM dithiothreitol (unless otherwise
indicated). Samples were separated on 10% or 15% SDS-PAGE gels,
transferred to PVDFmembranes (Immobilon-FL,Millipore), and blocked
with 5% (w/v) milk powder (Marvel) in Tris-buffered saline (pH 7.4) with
0.05% Tween-20 (TBST) for 1 h at room temperature. The membranes
were incubated with primary antibodies overnight at 4 ∘C, washed with
TBST and probed with appropriate secondary antibodies conjugated to
Li-COR IRDye fluorophores at room temperature before imaging on a
Li-COR Odyssey system. Quantification of band fluorescence intensity
was performed using the ODYSSEY software.
Antibodies were used at the following pre-determined dilutions from
stocks (listed above): anti-SFV E1/E2 1:1000, anti-IFITM1-NTD 1:1000,
anti-IFITM3-NTD 1:500, anti-VDAC 1:300, anti-tubulin 1:1000. Both
Li-COR secondary antibodies were used at 1:10 000.
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this article:
Figure S1: IFITM3 Y20A localizes to the plasma membrane.
P2-IFITM3-HA (wild type; WT) and P2-IFITM3-Y20A-HA cells
were fixed, permeabilized and labeled with anti-IFITM1-NTD anti-
bodies (which cross-react with IFITM3) followed by AF488 (green).
The images were captured using an epifluorescence microscope. WT
IFITM3 was seen in intracellular compartments (also see Figure 3),
where as IFITM3-Y20A-HA was seen at the plasma membrane. Nuclei
were detected with Hoechst staining. Scale bar represents 15 μm.
Figure S1 – Associated with Figures 2 and 8. The figure displays the
localization of the IFITM3-Y20A mutant, compared to wild type. This
localization has been published by others, and is included here as a
demonstration of the plasma membrane localization of the mutant in this
system.
Figure S2: Internalized SFV colocalizes with EEA1.A) SFV (50 pfu/cell)
was bound to A549 cells for 1 h at 4∘C prior to warming for the indicated
periods to promote endocytic uptake. Cells were then fixed and labeled
for SFV E1/E2 and EEA1, and visualized with AF488 (green, E1/E2) and
AF647 (magenta, EEA1). Single confocal sections are displayed. As seen
in Figure 5, E1/E2 labelling at 0 and 5min was seen as small puncta.
At later time points following endocytosis, larger and brighter puncta
were seen. EEA1 and E1/E2 were seen to overlap from 10min, indicating
trafficking of SFV to early endosomes. The apparent increase in EEA1
intensity with time was also seen in mock-infected samples (data not
shown), and may be due to cooling and warming the cells. Nuclei were
detectedwithHoechst staining. Scale bar represents 15 μm.B)Theoverlap
between green (SFV E1/E2) and magenta (EEA1) pixels was quantified
over multiple experiments (see Materials and Methods). A total of three
independent experiments were performed, and six images taken at 63×
magnification. The average ratio of the relative area of overlapping pixels
(green andmagenta) to green pixels from each experiment is plotted, with
the standard deviation used for the error bars. Figure S2 – Associated
with Figure 5. This figure is equivalent to the data in Figure 5, but is
performed in the control A549 cells, stained for EEA1 and SFV, rather
than staining for IFITM3-HA as in Figure 5.
Figure S3: EM imaging of SFVuptake. SFV (1000 pfu/cell) was bound to
A549, or OS-IFITM3-HA expressing cells for 1 h at 4∘C prior to warming
for the indicated periods to promote endocytic uptake. Samples were fixed
and processed for Epon section EM, as detailed inMaterials andMethods.
Virus particles were seen at the plasmamembrane at 0min, then in coated
vesicles after 5min at 37∘C. By 20 and 30min, virus particles appear
in endosomal structures, but it was hard to distinguish viral particles
from other intraluminal vesicles. Figure S3 – Associated with Figure 5.
This figure displays Epon EM micrographs for SFV internalization to
complement the IF data of Figure 5.
Figure S4: Immuno-gold labelling of cryosections and EM imaging
of SFV uptake. SFV (5000 pfu/cell) was bound to cells and allowed
to internalize, prior to processing for cryosectioning and immunogold
labelling. A) Sections were labeled with antibodies against SFV E1/E2.
Viral particles were detected at the cell surface at 0min. By 30min
viral particles were found within multivesicular bodies in both A549
and OS-IFITM3-HA expressing cells. B) Sections were labeled for SFV
E1/E2 and the HA-tag. The primary antibodies were detected with 10 nm
colloidal gold (SFV) or 15 nm colloidal gold (HA) conjugated secondary
antibodies. There was minimal HA background detected in the A549
cells, whereas most HA labelling in the IFITM3-HA cells was associated
with multivesicular bodies, where SFV particles were detected following
30min at 37∘C. Scale bars represent 200 nm. Figure S4 – Associated with
Figure 5. This figure displays immuno-gold labeled cryosections and EM
micrographs for SFV internalization to complement the IF data of Figure 5
Figure S5: Kinetics of SFV penetration into A549 cells. SFV (5 pfu/cell)
was bound to A549 cells for 1 h at 4∘C prior to warming to 37∘C
with media containing DMSO or 10 μM monensin to allow endocytic
uptake. At time points between 3 and 30min, DMSO containing media
was replaced with media containing monensin. After 5.5–6 h infection,
the cells were fixed and analyzed for infection by immunofluorescence
microscopy. The data show the percentage of infected cells compared to
DMSO controls. Although monensin added at early time points effec-
tively inhibited infection, addition at 30min had almost no effect.Thedata
displayed are mean infection percentage from three independent infec-
tions (each containing duplicates of each sample) with standard deviation
between experiments as error bars. Figure S5 – Associated with Figures 4
and 5, 6 and 7. This figure details the results for the monensin time of
addition experiment to determine the time course for SFV passing the
pH-dependent step of entry.
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